Molecular interaction of a potent nonpeptide agonist with the chemokine receptor CCR8

Molecular Pharmacology

Volumn 72, Issue 2, 2007, Pages 327-340

  Jensen, Pia C ^a   Nygaard, Rie ^a   Thiele, Stefanie ^a   Elder, Amy ^b   Zhu, Guoming ^b   Kolbeck, Roland ^b   Ghosh, Shomir ^b   Schwartz, Thue W ^a   Rosenkilde, Mette M ^a,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 2 [1 [3 (2 METHOXYPHENOXY)BENZYL] 4 HYDROXYPIPERIDIN 4 YL]BENZOIC ACID; 2 [2 [4 (3 PHENOXYBENZYL)PIPERAZIN 1 YL]ETHOXY]ETHANOL; 8 [3 (2 METHOXYPHENOXY)BENZYL] 1 PHENETHYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; ALANINE; CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR8; GLUTAMIC ACID; LMD 009; LMD 174; LMD 268; LMD 584; LMD 902; N ETHYL 2 4 METHOXYBENZENESULFONAMIDE; N [1 [3 (2 METHOXYPHENOXY)BENZYL]PIPERIDIN 4 YL] 1,2,3,4 TETRAHYDRO 2 OXOQUINOLINE 4 CARBOXAMIDE; N [1 [3 (2 METHOXYPHENOXY)BENZYL]PIPERIDIN 4 YL] 2 PHENYL 4 (PYRROLIDIN 1 YL)BUTANAMIDE; PHENYLALANINE; UNCLASSIFIED DRUG; ZK 756326;

ANIMAL CELL; ARTICLE; BINDING SITE; CALCIUM TRANSPORT; CHEMOTAXIS; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

EID: 34547177384     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.035543     Document Type: Article

References (40)

1. Baldwin JM (1993) The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12:1693-1703.
2. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors, in Receptor Molecular Biology (Sealfon SC ed), pp 366-428, Academic Press, New York.
3. Berkhout TA, Blaney FE, Bridges AM, Cooper DG, Forbes IT, Gribble AD, Groot PH, Hardy A, Ife RJ, Kaur R, et al. (2003) CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem 46:4070-4086.
4. Castonguay LA, Weng Y, Adolfsen W, Di Salvo J, Kilburn R, Caldwell CG, Daugherty BL, Finke PE, Hale JJ, Lynch CL, et al. (2003) Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 42:1544-1550.
5. Chensue SW, Lukacs NW, Yang TY, Shang X, Frait KA, Kunkel SL, Kung T, Wiekowski MT, Hedrick JA, Cook DN, et al. (2001) Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J Exp Med 193:573-584.
6. Dairaghi DJ, Fan RA, McMaster BE, Hanley MR, and Schall TJ (1999) HHV8-encoded VMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J Biol Chem 274:21569- 21574.
7. Damon I, Murphy PM, and Moss B (1998) Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. Proc Natl Acad Sci 95:6403-6407.
8. de Mendonça FL, da Fonseca PC, Phillips RM, Saldanha JW, Williams TJ, and Pease JE (2005) Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J Biol Chem 280:4808-4816.
9. Farrens DL, Altenbach C, Yang K, Hubbell WL, and Khorana HG (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274:768-770.
10. Gerard C and Rollins BJ (2001) Chemokines and disease. Nat Immunol 2:108-115.
11. Ghosh S, Elder A, Guo J, Mani U, Patane M, Carson K, Ye Q, Bennett R, Chi S, Jenkins T, et al. (2006) Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8). J Med Chem 49:2669-2672.
12. Govaerts C, Blanpain C, Deupi X, Ballet S, Ballesteros JA, Wodak SJ, Vassart G, Pardo L, and Parmentier M (2001) The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation. J Biol Chem 276:13217-13225.
13. Haskell CA, Horuk R, Liang M, Rosser M, Dunning L, Islam I, Kremer L, Gutierrez J, Marquez G, Martinez A, et al. (2006) Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Mol Pharmacol 69:309-316.
14. Hemmerich S, Paavola C, Bloom A, Bhakta S, Freedman R, Grunberger D, Krstenansky J, Lee S, McCarley D, Mulkins M, et al. (1999) Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2. Biochemistry 38:13013-13025.
15. Holst B, Lang M, Brandt E, Bach A, Howard A, Frimurer TM, Beck-Sickinger A, and Schwartz TW (2006) Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor. Mol Pharmacol 70:936-946.
16. Horuk R (2003) Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 29:369-375.
17. Horuk R, Clayberger C, Krensky AM, Wang Z, Grone HJ, Weber C, Weber KS, Nelson PJ, May K, Rosser M, et al. (2001) A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem 276:4199-4204.
18. Jarnagin K, Grunberger D, Mulkins M, Wong B, Hemmerich S, Paavola C, Bloom A, Bhakta S, Diehl F, Freedman R, et al. (1999) Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2. Biochemistry 38:16167-16177.
19. Javitch JA, Shi L, and Liapakis G (2002) Use of the substituted cysteine accessibility method to study the structure and function of G protein-coupled receptors. Methods Enzymol 343:137-156.
20. Kostenis E (2001) Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends Pharmacol Sci 22:560-564.
21. Lüttichau HR, Stine J, Boesen TP, Johnsen AH, Chantry D, Gerstoft J, and Schwartz TW (2000) A highly selective CC chemokine receptor (CCR) 8 antagonist encoded by the poxvirus Molluscum contagiosum. J Exp Med 191:171-180.
22. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, Arnold E, et al. (2006) Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 281:12688-12698.
23. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, Mulkins M, Weatherhead GS, Lapierre JM, Dankwardt J, et al. (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 275:25562-25571.
24. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, and Power CA (2000) International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52:145-176.
25. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le T, I, Teller DC, Okada T, et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739-745.
26. Rosenkilde MM, Andersen MB, Nygaard R, Frimurer TM, and Schwartz TW (2007) Activation of the CXCR3 chemokine receptor through anchoring of a small molecule chelator ligand between TM-III, -IV, and -VI. Mol Pharmacol 71:930-941.
27. Rosenkilde MM, David R, Oerlecke I, ned-Jensen T, Geumann U, Beck-Sickinger AG, and Schwartz TW (2006) Conformational constraining of inactive and active states of a seven transmembrane receptor by metal ion site engineering in the extracellular end of transmembrane segment V. Mol Pharmacol 70:1892-1901.
28. Rosenkilde MM, Kledal TN, Brauner-Osborne H, and Schwartz TW (1999) Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J Biol Chem 274:956-961.
29. Rosenkilde MM and Schwartz TW (2006) GluVII:06 - a highly conserved and selective anchor point for non-peptide ligands in chemokine receptors. Curr Top Med Chem 6:1319-1333.
30. Schwartz TW (1994) Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotech 5:434-444.
31. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, and Elling CE (2006) Molecular mechanism of 7TM receptor activation - a global toggle switch model. Annu Rev Pharmacol Toxicol 46:481-519.
32. Schwarz MK and Wells TN (2002) New therapeutics that modulate chemokine networks. Nat Rev Drug Discov 1:347-358.
33. Schwede T, Kopp J, Guex N, and Peitsch MC (2003) SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 31:3381-3385.
34. Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, Palani A, Tagat JR, Clader JW, McCombie SW, Baroudy BM, et al. (2006) Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349:41-54.
35. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, and Javitch JA (2002) Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 277:40989-40996.
36. Soler D, Chapman TR, Poisson LR, Wang L, Cote-Sierra J, Ryan M, McDonald A, Badola S, Fedyk E, Coyle AJ, et al. (2006) CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes. J Immunol 177:6940-6951.
37. Trebst C, Staugaitis SM, Kivisakk P, Mahad D, Cathcart MK, Tucky B, Wei T, Rani MR, Horuk R, Aldape KD, et al. (2003) CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages. Am J Pathol 162:427-438.
38. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, et al. (2003) Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 77:5201-5208.
39. Vaidehi N, Schlyer S, Trabanino RJ, Floriano WB, Abrol R, Sharma S, Kochanny M, Koovakat S, Dunning L, Liang M, et al. (2006) Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J Biol Chem 281:27613-27620.
40. Watson C, Jenkinson S, Kazmierski W, and Kenakin T (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67:1268-1282.